title: [Bevacizumab therapy for a colorectal cancer patient or hemodialysis with hepatic metastasis].
abstract: We report our experience with a case of colorectal cancer treated with chemotherapy for a liver metastasis patient on hemodialysis. The patient was a 67-year-old man with a history of chronic renal failure, who was on hemodialysis since 2005. High anterior resection was performed for sigmoid colon and rectal cancer in January, 2010. After starting chemotherapy while planning to use FOLFOX6+bevacizumab(BV)as a postoperative standard chemotherapy, in combination with hemodialysis three times a week while performing dose escalation, administration postponement was continued for myelosuppression that was considered to be the effect of oxaliplatin. Oxaliplatin was administered for only 2 courses, and was then changed to BV+sLV5FU2 therapy. We continued treating the metastases approximately on schedule. Imaging revealed, the liver metastases were CR because they had disappeared. The BV use case of the dialysis case had few reports, but was thought to be able to use it by careful administration safely.
authors.affiliation: Dept. of Surgery, Fukui Prefectural Hospital, Japan.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Sato
authors.forename: Kenji
authors.initials: K
authors.lastname: Doden
authors.forename: Yoji
authors.initials: Y
authors.lastname: Nishida
authors.forename: Satsuki
authors.initials: S
authors.lastname: Shimizu
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Tanaka
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yagi
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Asaumi
authors.forename: Yasumitsu
authors.initials: Y
authors.lastname: Hirano
authors.forename: Kazuya
authors.initials: K
authors.lastname: Maeda
authors.forename: Tamon
authors.initials: T
authors.lastname: Miyanaga
authors.forename: Masakazu
authors.initials: M
authors.lastname: Hattori
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hashizume
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D006435:Renal Dialysis; D012811:Sigmoid Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil